Number of Circulating Tumor Cells Up After Surgery in SCCHN

This article originally appeared here.
Share this content:
Number of Circulating Tumor Cells Up After Surgery in SCCHN
Number of Circulating Tumor Cells Up After Surgery in SCCHN

FRIDAY, June 17, 2016 (HealthDay News) -- Most patients with squamous cell carcinoma of the head and neck (SCCHN) have an increase in the number of circulating tumor cells (CTCs) after surgical resection, according to a study published online June 5 in Head & Neck.

Kris R. Jatana, M.D., from the Nationwide Children's Hospital in Columbus, Ohio, and colleagues identified cytokeratin-positive CTCs using a negative depletion technique. They compared the numbers of CTCs immediately before and after surgical resection using blood samples from 38 patients with SCCHN.

The researchers found that 79 percent of patients had CTCs before and after surgery. Overall, 7.89 percent of patients had no CTCs before surgery but did have CTCs after surgery. After surgery there was an increased number of CTCs/mL in 60.5 percent of patients, with a 6.63-fold mean increase (P = 0.02).

"The timing of blood sample collection for such solid cancers that undergo surgical intervention, such as SCCHN, can potentially impact the number of CTCs identified," the authors write. "Although a prognostic blood test for CTCs could have important treatment and surveillance implications, the viability and clinical significance of potentially surgically released CTCs in SCCHN is still not known."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »